The company didn’t explain the nature of these observations. Miryalaguda plant was one among the three plants for which the company got US drug regulator warning letter in November 2015. Money Control, 3 days ago
DRL gets 3 USFDA observations for Miryalaguda facility - Myiris, 3 days ago
Drug firm Dr Reddy's Laboratories today said the US health regulator has made three observations after completing inspection of its Miryalaguda facility.DNA, 4 days ago USFDA concludes inspection of Dr Reddy's Miryalaguda facility Money Today, 3 days ago Plants of Pharma major, Dr. Reddy's to be re-audited by USFDA India Infoline, 1 month ago USFDA to re-audit Dr Reddy's 3 plants Business Standard, 1 month ago
Posted by Equitymaster After opening the day in the green, the Indian share markets have continued to trade strong and are currently trading above the dotted line. With the exception of stocks in the FMCG sector all sectoral indices are trading on a positive ...Equitymaster.com, 4 weeks ago
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator. Seoul-based biotech company Mezzion Pharma has filed a suit against Dr Reddy’s Laboratories in a US court. It has alleged the Hyderabad-based supplier had committed fraud by hiding significant deficiencies in the Current Good Manufacturing Practice, or CGMP, regulations enforced by the US health regulator. In the suit, filed in the state of New Jersey, Mezzion seeks to “recover ...Rediff.com, 4 weeks ago
on your WebpageAdd Widget >Get your members hooked!